Major U.S. pharmaceutical companies are set to increase the prices of some of their most popular prescription drugs, including the breast cancer medication Ibrance.
Following major recalls of Chinese-manufactured medication that contained carcinogenic ingredients, lawmakers expressed their alarm, and sometimes disbelief, at the FDA's inability to regulate foreign suppliers at a Tuesday hearing.
The drug company is pulling batches of the drug distributed between July and August 2019.
The indictment charges claim that name-brand drugs intended to treat conditions for cancer, HIV and mental illness were obtained through an underground market, fraud, burglary and cargo theft for resale purposes.
The study, published in JAMA, is based on government reports, articles and peer-reviewed publications related to costs and savings estimates in six categories of waste, released between 2012 and 2019.
China and our other economic competitors would love to see us undermine our own domestic biopharmaceutical sector to their benefit.
"If we #BoycottCVS, we are also saving a rainforest. So, two birds," Handler tweeted.
Scientists also found ketamine and a banned pesticides in shrimp.
Prescrypto provides a blockchain-based infrastructure to collect prescribing information, route that information securely to pharmacies, and provide a history of medications used by each patient.
An AI breakthrough could lead to a silver bullet for Alzheimer's and offer a faster, cheaper way to find life-changing drugs.
Though gene therapies can be expensive on their own, they should only need to be administered once.
Even after five years on the market, the promised benefits aren't showing up.
From medications to play dough, people with celiac disease should avoid them.
The use of nitroprusside and isoproterenol dropped by 53 percent and 35 percent over three years, as their prices skyrocketed by factors of ten.
Marathon Pharmaceuticals' newly approved drug is now on hold after patient advocates and policymakers criticized its expensive price.
Takeda CFO James Kehoe said the company was on the hunt for hit drugs.
A new report finds it takes an average of 10 months for the federal regulatory agency to sign off on sales of new pharmaceuticals.